Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply.

Goncalves, J; Magro, F; Danese, S; Lakatos, P L; Ben-Horin, S

Goncalves, J; Magro, F; Danese, S; Lakatos, P L; Ben-Horin, S.

Affiliation

Goncalves J; Research Institute for Medicines (iMed ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.
Magro F; Gastroenterology Department, Faculty of Medicine, University of Porto, Centro Hospitalar São João, Porto, Portugal.
Danese S; Department of Biomedical Sciences, Humanitas University, Humanitas Clinical and Research Centre, Milan, Italy.
Lakatos PL; First Department of Medicine, Semmelweis University, Budapest, Hungary.
Ben-Horin S; Division of Gastroenterology, McGill University, MUHC, Montreal General Hospital, Montreal, QC, Canada.

Aliment Pharmacol Ther ; 48(5): 575-576, 2018 09.

Article in En | MEDLINE | ID: mdl-30156326

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Biosimilar Pharmaceuticals Limits: Humans Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2018 Document type: Article Affiliation country: Portugal Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google